Abstract 2126P
Background
The beneficial effects of exercise for cancer patients are well recognized but implemented exercise programs remain scarce, especially for patients during medical treatment. For that reason, we developed a supervised, personalized exercise concept for cancer patients, implemented into a clinical, oncological setting.
Methods
Cancer patients before, during or eventually after their medical treatment with an identified need for exercise could participate in a free of charge exercise intervention for at least three months at the University Hospital Cologne, Germany. We recorded demographic and medical data at enrolment and exercise adherence up to one year.
Results
A sample of n=1.660 patients attended the exercise program. The majority of patients were female (70%), under medical treatment (65%), diagnosed with breast cancer (40%), without metastasis or severe comorbidities (>70%) and on average 54 years old. The median time between diagnosis and exercise participation differed in patients during medical treatment (4 months), patients with metastasis (7 months) and cancer survivors (11 months). Almost one third (31%) discontinued exercise within the first two weeks of participation. Prolonged exercise (median: 19 weeks) was achieved by one third (32%) of the patients. The average exercise adherence was ∼1 session a week with <3% of patients reaching ≥2 sessions a week
Conclusions
To our knowledge, this is the worlds-first report of a professional, supervised exercise program tailored for cancer patients under medical treatment implemented into a clinical setting with >1.600 patients. We described the population that was referred to an exercise program, identified barriers to exercise participation and observed an important mismatch between recommendations and real-world exercise data. Exercise participation was engaged ≥4months after diagnosis and only a third of the patients exercised longer than three months. Almost all patients undercut the well-established exercise recommendations of ≥2 sessions a week. Future implementation concepts should optimize exercise initiation timely after diagnosis and adherence levels due to innovative exercise approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Cologne, Cologne, Germany.
Funding
German Cancer Aid.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06